Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Income (2016 - 2025)

Historic Operating Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.8 million.

  • Lineage Cell Therapeutics' Operating Income rose 140.62% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.2 million, marking a year-over-year decrease of 5477.78%. This contributed to the annual value of -$21.5 million for FY2024, which is 1316.06% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Operating Income stood at -$3.8 million, which was up 140.62% from -$19.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Operating Income high stood at -$3.8 million for Q3 2025, and its period low was -$28.2 million during Q4 2021.
  • Its 5-year average for Operating Income is -$7.8 million, with a median of -$6.5 million in 2025.
  • In the last 5 years, Lineage Cell Therapeutics' Operating Income plummeted by 38007.48% in 2021 and then soared by 7648.91% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Operating Income stood at -$28.2 million in 2021, then surged by 76.49% to -$6.6 million in 2022, then grew by 4.17% to -$6.4 million in 2023, then increased by 19.68% to -$5.1 million in 2024, then grew by 25.91% to -$3.8 million in 2025.
  • Its Operating Income stands at -$3.8 million for Q3 2025, versus -$19.8 million for Q2 2025 and -$6.5 million for Q1 2025.